Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • alunem
    Junior Member
    • Feb 2011
    • 5

    #1

    MiSeqDx specifications

    What are the specifications of the FDA-cleared version of the MiSeq. As I understood, it's a downgrade version of it (as it had to be locked since the beginning of FDA application processing), but what exactly?
    - what is the expected ouput (number of reads, lenght...)
    - what files are going to be available for the user? (are we going to have access to fastq files? bcl?)

    Well, it's not easy to find these information on illumina's website.

    Thanks!
  • GenoMax
    Senior Member
    • Feb 2008
    • 7142

    #2
    http://res.illumina.com/documents/pr...instrument.pdf

    Comment

    • alunem
      Junior Member
      • Feb 2011
      • 5

      #3
      Thanks, this answers my first question. Any idea about files available after sequencing processed?

      Comment

      • GenoMax
        Senior Member
        • Feb 2008
        • 7142

        #4
        You may want to check with your local FAS (who can in turn check with someone here in the US, if the instrument is not available in France).

        My feeling (speculation) is the output may be some kind of a summary report saying such and such mutation is present/absent. No data may be directly accessible. Someone who has a MiSeqDX perhaps can provide additional information.

        Comment

        • NextGenSeq
          Senior Member
          • Apr 2009
          • 482

          #5
          Wonder how they dealt with the well known carryover contamination issue. This would be a major problem for viral or tumor sequencing.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
            by SEQadmin2



            Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

            Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
            ...
            Today, 09:55 AM
          • SEQadmin2
            New Genomics Technologies Take Aim at Long-Standing Limits
            by SEQadmin2


            Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

            We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
            ...
            09-28-2026, 10:25 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, Today, 05:39 AM
          0 responses
          11 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, Yesterday, 09:56 AM
          0 responses
          14 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-09-2026, 11:14 AM
          0 responses
          27 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 09-29-2026, 09:51 AM
          0 responses
          77 views
          0 reactions
          Last Post SEQadmin2  
          Working...